Prolife at CPHI 2025: Smart 2-in-1 Cardiovascular Screening

From October 28 to 30, Prolife took part in CPHI Frankfurt 2025 — one of Europe’s key pharmaceutical events. Across three days, we met hundreds of partners from pharmacy, retail, and e-commerce, receiving strong confirmation of the market’s interest in preventive cardiovascular diagnostics.

2-in-1 Stroke Risk Screening

Buyers and distributors consistently highlighted demand for technologies that detect two major stroke risk factors in one measurement: high blood pressure and atrial fibrillation.

Our flagship PX7 Premium delivers exactly this through:

ComfortPro Technology for faster, gentler readings
AI Measurement for personalized accuracy
AFIB Smart for silent AF detection

This combination resonated strongly with partners seeking clinically reliable, easy-to-use solutions for home monitoring and pharmacy services.

Design That Builds Trust

PX7 Premium impressed visitors with its ultra-thin form, curved glass surface, and bright VA display, reinforcing Prolife’s commitment to combining precision with modern, consumer-ready design.

Shaping Preventive Healthcare

CPHI 2025 confirmed that intelligent cardiovascular screening is becoming a core category for health-focused brands. Prolife is ready to support partners with technology that brings early prevention into everyday life.

Prolife — Trust the Best.